{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:18:31Z","timestamp":1790864311918,"version":"4.1.0"},"reference-count":206,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2010,6,21]],"date-time":"2010-06-21T00:00:00Z","timestamp":1277078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2010,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Human papillomavirus and Herpes simplex virus are the most common genital viral infections encountered in clinical practice worldwide. We reviewed the literature focusing on new and experimental treatment modalities for both conditions, based on to the evidence\u2010based data available. The modalities evaluated include topical agents such as immune response modifiers (imiquimod, resiquimod, and interferon), antivirals (penciclovir, cidofovir, and foscarnet), sinecatechins, microbiocidals (SPL7013 gel, and PRO 2000 gel), along with experimental (oligodeoxynucleotides), immunoprophylactic, and immunotherapeutic vaccines.<\/jats:p>","DOI":"10.1111\/j.1365-4632.2009.04375.x","type":"journal-article","created":{"date-parts":[[2015,10,13]],"date-time":"2015-10-13T05:21:08Z","timestamp":1444713668000},"page":"733-749","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Herpes simplex virus and human papillomavirus genital infections: new and investigational therapeutic options"],"prefix":"10.1111","volume":"49","author":[{"given":"Martha H.","family":"Viera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadegh","family":"Amini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sailesh","family":"Konda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Block","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Berman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,6,21]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.8.964"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2007.07.076"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/sti.76.3.162"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/014107687807100305"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1089\/gyn.1995.11.41"},{"key":"e_1_2_8_7_2","first-page":"521","article-title":"Therapeutic value of trichloroacetic acid in the treatment of isolated genital warts on the external female genitalia","volume":"52","author":"Taner ZM","year":"2007","journal-title":"J Reprod Med"},{"key":"e_1_2_8_8_2","first-page":"92","article-title":"Quercetin and kaempherol: an argument against the use of podophyllin?","volume":"71","author":"Petersen CS","year":"1995","journal-title":"Genitourin Med"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/77.4.478"},{"key":"e_1_2_8_10_2","first-page":"237","article-title":"Podophyllum toxicity: case report and literature review","volume":"9","author":"Moher LM","year":"1979","journal-title":"J Fam Pract"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200767150-00006"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.7.1869-1873.2000"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.4.789"},{"key":"e_1_2_8_14_2","first-page":"297","article-title":"Subcutaneous interferon alpha 2a combined with cryotherapy vs cryotherapy alone in the treatment of primary anogenital warts: a randomised observer blind placebo controlled study","volume":"67","author":"Handley JM","year":"1991","journal-title":"Genitourin Med"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1258\/095646207781024711"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1258\/ijsa.2007.007196"},{"key":"e_1_2_8_17_2","first-page":"153","article-title":"Study of persistence and recurrence rates in 106 patients with condyloma and intraepithelial neoplasia after CO2 laser treatment","volume":"18","author":"Aynaud O","year":"2008","journal-title":"Eur J Dermatol"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1159\/000065844"},{"key":"e_1_2_8_19_2","first-page":"5","article-title":"Pulsed dye laser versus podophyllin resin in treatment of female genital warts","volume":"3","author":"Abeer A","year":"2007","journal-title":"Egypt Dermatol Online J"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/14764170600617490"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1159\/000017906"},{"key":"e_1_2_8_22_2","first-page":"15","article-title":"Veregen: a botanical for treatment of genital warts","volume":"50","year":"2008","journal-title":"Med Lett Drugs Ther"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10350-004-7287-5"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021641"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.8.4.421"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(05)70101-7"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1201-9712(07)60017-4"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.07.051"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17398-4"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20071311"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.00033-08"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1155\/2007\/942650"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.5070\/D36KS5T6QW"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0b013e3282f486c9"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04426.x"},{"key":"e_1_2_8_36_2","first-page":"1","article-title":"Epidermodysplasia verruciformis in the setting of HIV infection","volume":"14","author":"Chen P","year":"2008","journal-title":"Dermatol Online J"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.11474"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-200203000-00001"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-200208000-00001"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006250-200304000-00007"},{"key":"e_1_2_8_41_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.12.1.1","article-title":"Genital herpes: review of the epidemic and potential use of type\u2010specific serology","volume":"12","author":"Ashley RL","year":"1999","journal-title":"Clin Microbiol Rev"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-116-3-197"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199509213331205"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/45.suppl_4.1"},{"key":"e_1_2_8_45_2","unstructured":"Sexually Transmitted Diseases Treatment Guidelines 2006. Department of Health and Human Services. Centers for Disease Control and Prevention (CDC). Available at:http:\/\/www.cdc.gov\/std\/treatment\/2006\/genital\u2010ulcers.htm. Accessed June 19 2009."},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1086\/339325"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1086\/498521"},{"key":"e_1_2_8_48_2","doi-asserted-by":"publisher","DOI":"10.1086\/339326"},{"key":"e_1_2_8_49_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04139.x"},{"key":"e_1_2_8_50_2","first-page":"110","article-title":"Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study Group","volume":"73","author":"Bodsworth NJ","year":"1997","journal-title":"Genitourin Med"},{"key":"e_1_2_8_51_2","first-page":"105","article-title":"Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. International Valaciclovir HSV Study Group","volume":"73","author":"Patel R","year":"1997","journal-title":"Genitourin Med"},{"key":"e_1_2_8_52_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-199709000-00007"},{"key":"e_1_2_8_53_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.10.887"},{"key":"e_1_2_8_54_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1997.00440240109016"},{"key":"e_1_2_8_55_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-200303000-00010"},{"key":"e_1_2_8_56_2","doi-asserted-by":"publisher","DOI":"10.1258\/095646207781147328"},{"key":"e_1_2_8_57_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035144"},{"key":"e_1_2_8_58_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.olq.0000237853.69443.71"},{"key":"e_1_2_8_59_2","doi-asserted-by":"publisher","DOI":"10.1136\/sti.78.6.435"},{"key":"e_1_2_8_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(99)00052-2"},{"key":"e_1_2_8_61_2","first-page":"1015","article-title":"Topical imiquimod for acyclovir\u2010unresponsive herpes simplex virus 2 infection","volume":"137","author":"Gilbert J","year":"2001","journal-title":"Arch Dermatol"},{"key":"e_1_2_8_62_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2002.504412.x"},{"key":"e_1_2_8_63_2","first-page":"132","article-title":"Recurrent urogenital herpes simplex successful treatment with imiquimod?","volume":"75","author":"Christensen B","year":"1999","journal-title":"Sex Transm Infect"},{"key":"e_1_2_8_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2005.06.037"},{"key":"e_1_2_8_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.06.024"},{"key":"e_1_2_8_66_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.10.3243-3248.2002"},{"key":"e_1_2_8_67_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01173-07"},{"key":"e_1_2_8_68_2","doi-asserted-by":"publisher","DOI":"10.1086\/513276"},{"key":"e_1_2_8_69_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/142.6.943"},{"key":"e_1_2_8_70_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/154.3.437"},{"key":"e_1_2_8_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-3542(92)90044-6"},{"key":"e_1_2_8_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)92723-7"},{"key":"e_1_2_8_73_2","first-page":"125","article-title":"Increased effects of topically applied interferon on herpes simplex virus\u2010induced lesions by caffeine","volume":"39","author":"Vonka V","year":"1995","journal-title":"Acta Virol"},{"key":"e_1_2_8_74_2","doi-asserted-by":"publisher","DOI":"10.1159\/000247902"},{"key":"e_1_2_8_75_2","unstructured":"VivaGel\u2122.An expanded phase i randomized placebo controlled trial of the safety and tolerability of 3% w\/w SPL7013 gel (VivaGel\u2122) in healthy young women when administered twice daily for 14 days. Clinical Trial Results Appendix \u2013 Study No. SPL7013\u2010004. ClinicalTrials.gov identifier: NCT00331032. Available at:http:\/\/www.starpharma.com\/data\/080512%20Starpharma%20reports%20positive%20VivaGel%20clinical%20study%20results.pdf. Accessed on June 19 2009"},{"key":"e_1_2_8_76_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki056"},{"key":"e_1_2_8_77_2","doi-asserted-by":"publisher","DOI":"10.1086\/498533"},{"key":"e_1_2_8_78_2","doi-asserted-by":"publisher","DOI":"10.1038\/35047123"},{"key":"e_1_2_8_79_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.16.8948-8956.2003"},{"key":"e_1_2_8_80_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.10518"},{"key":"e_1_2_8_81_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.2.953-962.2003"},{"key":"e_1_2_8_82_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.22.11387-11396.2002"},{"key":"e_1_2_8_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2005.10.007"},{"key":"e_1_2_8_84_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg481"},{"key":"e_1_2_8_85_2","first-page":"437","article-title":"Herpes simplex virus type 2 vaccines: new ground for optimism?","volume":"11","author":"Aurelian L","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"key":"e_1_2_8_86_2","doi-asserted-by":"crossref","first-page":"889","DOI":"10.7326\/0003-4819-122-12-199506150-00001","article-title":"A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected]","volume":"122","author":"Langenberg AG","year":"1995","journal-title":"Ann Intern Med"},{"issue":"3","key":"e_1_2_8_87_2","first-page":"161A","article-title":"Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines","volume":"11","author":"Stanberry LR","year":"2004","journal-title":"Herpes"},{"key":"e_1_2_8_88_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011915"},{"key":"e_1_2_8_89_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/161.4.653"},{"key":"e_1_2_8_90_2","doi-asserted-by":"publisher","DOI":"10.1038\/jid.1938.26"},{"key":"e_1_2_8_91_2","first-page":"351","article-title":"Immunotherapy with inactivated polyvalent herpes vaccines","volume":"52","author":"Dundarov S","year":"1982","journal-title":"Dev Biol Stand"},{"key":"e_1_2_8_92_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1964.01590300072021"},{"key":"e_1_2_8_93_2","first-page":"105","article-title":"Results of treatment with the Herpes simplex antigen Lupidon H, resp. Lupidon G","volume":"50","author":"Schmersahl P","year":"1975","journal-title":"Z Hautkr"},{"key":"e_1_2_8_94_2","doi-asserted-by":"publisher","DOI":"10.1177\/095646249500600611"},{"key":"e_1_2_8_95_2","first-page":"625","article-title":"Controlled clinical study of the herpes antigens LUPIDON H and LUPIDON G","volume":"52","author":"Weitgasser H","year":"1977","journal-title":"Z Hautkr"},{"key":"e_1_2_8_96_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890160206"},{"key":"e_1_2_8_97_2","first-page":"333","article-title":"Early experience with \u201cantigenoid\u201d vaccine Ac NFU1(S\u2010) MRC towards prevention or modification of herpes genitalis","volume":"52","author":"Skinner GR","year":"1982","journal-title":"Dev Biol Stand"},{"key":"e_1_2_8_98_2","first-page":"311","article-title":"Efficacy of vaccine Ac NFU1 (S\u2010) MRC 5 given after an initial clinical episode in the prevention of herpes genitalis","volume":"59","author":"Woodman CB","year":"1983","journal-title":"Br J Vener Dis"},{"key":"e_1_2_8_99_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004300050043"},{"key":"e_1_2_8_100_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/167.5.1045"},{"key":"e_1_2_8_101_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)92581-X"},{"key":"e_1_2_8_102_2","doi-asserted-by":"publisher","DOI":"10.1086\/514103"},{"key":"e_1_2_8_103_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(00)00446-1"},{"key":"e_1_2_8_104_2","first-page":"235","article-title":"A double\u2010blind study of the efficacy and safety of the ICP10deltaPK vaccine against recurrent genital HSV\u20102 infections","volume":"70","author":"Casanova G","year":"2002","journal-title":"Cutis"},{"key":"e_1_2_8_105_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-10-200511150-00007"},{"key":"e_1_2_8_106_2","unstructured":"GlaxoSmithKline.Briefing document for the antiviral drugs advisory committee. May 14 2003. Available at:http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/03\/briefing\/3950B2_01_GlaxoSmithKline\u2010Valtrex.pdf. Accessed on June 19 2009."},{"key":"e_1_2_8_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61908-4"},{"key":"e_1_2_8_108_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.24.3100"},{"key":"e_1_2_8_109_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200006160-00019"},{"key":"e_1_2_8_110_2","doi-asserted-by":"publisher","DOI":"10.1258\/0956462021924550"},{"key":"e_1_2_8_111_2","doi-asserted-by":"publisher","DOI":"10.1086\/378416"},{"key":"e_1_2_8_112_2","doi-asserted-by":"publisher","DOI":"10.1086\/422755"},{"key":"e_1_2_8_113_2","doi-asserted-by":"publisher","DOI":"10.1002\/bdra.20013"},{"key":"e_1_2_8_114_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.obstetgynecol.2003.08.015"},{"key":"e_1_2_8_115_2","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2003.185"},{"key":"e_1_2_8_116_2","doi-asserted-by":"publisher","DOI":"10.1155\/S1064744902000054"},{"key":"e_1_2_8_117_2","first-page":"642","article-title":"Randomized, comparative trial on the sustained efficacy of topical imiquimod 5% cream versus conventional ablative methods in external anogenital warts","volume":"16","author":"Sch\u00f6fer H","year":"2006","journal-title":"Eur J Dermatol"},{"key":"e_1_2_8_118_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2004.tb00568.x"},{"key":"e_1_2_8_119_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.1.25"},{"key":"e_1_2_8_120_2","first-page":"273","article-title":"Cryotherapy versus electrocautery in the treatment of genital warts","volume":"57","author":"Simmons PD","year":"1981","journal-title":"Br J Vener Dis"},{"key":"e_1_2_8_121_2","first-page":"184","article-title":"Podophyllin 0.5% or 2.0% v podophyllotoxin 0.5% for the self treatment of penile warts: a double blind randomised study","volume":"73","author":"White DJ","year":"1997","journal-title":"Genitourin Med"},{"key":"e_1_2_8_122_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)92282-4"},{"key":"e_1_2_8_123_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(94)90168-6"},{"key":"e_1_2_8_124_2","first-page":"735","article-title":"A double\u2010blind, randomized trial of 0.5% podofilox and placebo for the treatment of genital warts in women","volume":"77","author":"Greenberg MD","year":"1991","journal-title":"Obstet Gynecol"},{"key":"e_1_2_8_125_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(90)90424-C"},{"key":"e_1_2_8_126_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.1.33"},{"key":"e_1_2_8_127_2","doi-asserted-by":"publisher","DOI":"10.1159\/000246818"},{"key":"e_1_2_8_128_2","doi-asserted-by":"publisher","DOI":"10.1136\/sti.79.4.270"},{"key":"e_1_2_8_129_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)91823-X"},{"key":"e_1_2_8_130_2","first-page":"91","article-title":"Recurrence of condylomata acuminata following cryotherapy is not prevented by systemically administered interferon","volume":"69","author":"Eron LJ","year":"1993","journal-title":"Genitourin Med"},{"key":"e_1_2_8_131_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-199320060-00008"},{"key":"e_1_2_8_132_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.1991.tb03642.x"},{"key":"e_1_2_8_133_2","first-page":"390","article-title":"Cryotherapy compared with trichloroacetic acid in treating genital warts","volume":"63","author":"Godley MJ","year":"1987","journal-title":"Genitourin Med"},{"key":"e_1_2_8_134_2","first-page":"16","article-title":"Treatment of external genital warts: a randomised clinical trial comparing podophyllin, cryotherapy, and electrodesiccation","volume":"66","author":"Stone KM","year":"1990","journal-title":"Genitourin Med"},{"key":"e_1_2_8_135_2","first-page":"59","article-title":"Refractory condylomata acuminata: a controlled clinical trial of carbon dioxide laser versus conventional surgical treatment","volume":"61","author":"Duus BR","year":"1985","journal-title":"Genitourin Med"},{"key":"e_1_2_8_136_2","first-page":"93","article-title":"Regression rate of clinical HPV infection of the lower genital tract during pregnancy after laser CO2 surgery","volume":"33","author":"Frega A","year":"2006","journal-title":"Clin Exp Obstet Gynecol"},{"key":"e_1_2_8_137_2","first-page":"99","article-title":"Systemic interferon alpha\u20102b increases the cure rate in laser treated patients with multiple persistent genital warts: a placebo\u2010controlled study","volume":"67","author":"Petersen CS","year":"1991","journal-title":"Genitourin Med"},{"key":"e_1_2_8_138_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(88)90375-4"},{"key":"e_1_2_8_139_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-108-5-675"},{"key":"e_1_2_8_140_2","first-page":"393","article-title":"Randomized clinical trial comparing systemic interferon with diathermocoagulation in primary multiple and widespread anogenital condyloma","volume":"74","author":"Benedetti Panici P","year":"1989","journal-title":"Obstet Gynecol"},{"key":"e_1_2_8_141_2","doi-asserted-by":"publisher","DOI":"10.1258\/0956462971918878"},{"key":"e_1_2_8_142_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3181719b60"},{"key":"e_1_2_8_143_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061760"},{"key":"e_1_2_8_144_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061741"},{"key":"e_1_2_8_145_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603469"},{"key":"e_1_2_8_146_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.07.002"},{"key":"e_1_2_8_147_2","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0b013e31815e4190"},{"issue":"1","key":"e_1_2_8_148_2","first-page":"24A","article-title":"Long\u2010term suppressive therapy with acyclovir for recurrent genital herpes","volume":"22","author":"Baker DA","year":"1994","journal-title":"J Int Med Res"},{"key":"e_1_2_8_149_2","doi-asserted-by":"publisher","DOI":"10.1159\/000249257"},{"key":"e_1_2_8_150_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-2115(00)00406-1"},{"key":"e_1_2_8_151_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/12.suppl_B.61"},{"key":"e_1_2_8_152_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198304213081602"},{"key":"e_1_2_8_153_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198406143102402"},{"key":"e_1_2_8_154_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(82)90118-8"},{"key":"e_1_2_8_155_2","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/archderm.1993.01680260052005","article-title":"Long\u2010term suppression of recurrent genital herpes with acyclovir. A 5\u2010year benchmark. acyclovir study group","volume":"129","author":"Goldberg LH","year":"1993","journal-title":"Arch Dermatol"},{"key":"e_1_2_8_156_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890410510"},{"key":"e_1_2_8_157_2","doi-asserted-by":"publisher","DOI":"10.1086\/424519"},{"key":"e_1_2_8_158_2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2340\/00015555655963","article-title":"Oral acyclovir suppression of recurrent genital herpes: a double\u2010blind, placebo\u2010controlled, crossover study","volume":"65","author":"Halsos AM","year":"1985","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_8_159_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1991.03460060079028"},{"key":"e_1_2_8_160_2","first-page":"387","article-title":"Acyclovir prophylaxis of recurrent genital herpes: randomised placebo controlled crossover study","volume":"61","author":"Kinghorn GR","year":"1985","journal-title":"Genitourin Med"},{"key":"e_1_2_8_161_2","first-page":"298","article-title":"Oral acyclovir suppressive therapy in severe recurrent genital herpes. A double\u2010blind, placebo\u2010controlled cross\u2010over study","volume":"36","author":"Kroon S","year":"1989","journal-title":"Dan Med Bull"},{"key":"e_1_2_8_162_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1984.03350090023017"},{"key":"e_1_2_8_163_2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jama.1988.03410020067030","article-title":"Long\u2010term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double\u2010blind trial","volume":"260","author":"Mertz GJ","year":"1988","journal-title":"JAMA"},{"key":"e_1_2_8_164_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)91725-4"},{"key":"e_1_2_8_165_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)90237-X"},{"key":"e_1_2_8_166_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(82)90658-4"},{"key":"e_1_2_8_167_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1984.03340400031020"},{"key":"e_1_2_8_168_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(82)90119-X"},{"key":"e_1_2_8_169_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/16.5.621"},{"key":"e_1_2_8_170_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-198801000-00013"},{"key":"e_1_2_8_171_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198406143102401"},{"key":"e_1_2_8_172_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/16.2.219"},{"key":"e_1_2_8_173_2","first-page":"876","article-title":"Prolonged treatment with acyclovir in recurrent genital herpes. clinical, virological, and immunological response","volume":"119","author":"Velasco M","year":"1991","journal-title":"Rev Med Chil"},{"key":"e_1_2_8_174_2","doi-asserted-by":"publisher","DOI":"10.1086\/383038"},{"key":"e_1_2_8_175_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1996.03540010046029"},{"key":"e_1_2_8_176_2","doi-asserted-by":"publisher","DOI":"10.1086\/444457"},{"key":"e_1_2_8_177_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200607040-00001"},{"key":"e_1_2_8_178_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10227-002-0141-2"},{"key":"e_1_2_8_179_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2005.11.051"},{"key":"e_1_2_8_180_2","doi-asserted-by":"publisher","DOI":"10.4065\/81.10.1321"},{"key":"e_1_2_8_181_2","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0b013e31816d1f42"},{"key":"e_1_2_8_182_2","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/01.olq.0000243620.13718.56","article-title":"Suppressive therapy with valacyclovir in early genital herpes: a pilot study of clinical efficacy and herpes\u2010related quality of life","volume":"34","author":"Handsfield HH","year":"2007","journal-title":"Sex Transm Dis"},{"key":"e_1_2_8_183_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062607"},{"key":"e_1_2_8_184_2","doi-asserted-by":"publisher","DOI":"10.1086\/515385"},{"key":"e_1_2_8_185_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000219749.96274.15"},{"key":"e_1_2_8_186_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1996.00440140169018"},{"key":"e_1_2_8_187_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-3542(84)90034-2"},{"key":"e_1_2_8_188_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198206033062201"},{"key":"e_1_2_8_189_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(82)90117-6"},{"key":"e_1_2_8_190_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/12.suppl_B.79"},{"key":"e_1_2_8_191_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/12.suppl_B.67"},{"key":"e_1_2_8_192_2","first-page":"186","article-title":"Efficacy of combined treatment with oral and topical acyclovir in first episode genital herpes","volume":"62","author":"Kinghorn GR","year":"1986","journal-title":"Genitourin Med"},{"key":"e_1_2_8_193_2","first-page":"847","article-title":"Acyclovir creme in recurrent herpes genitalis","volume":"109","author":"Laerum E","year":"1989","journal-title":"Tidsskr Nor Laegeforen"},{"key":"e_1_2_8_194_2","first-page":"116","article-title":"Topical acyclovir in the treatment of initial genital herpes","volume":"59","author":"Thin RN","year":"1983","journal-title":"Br J Vener Dis"},{"key":"e_1_2_8_195_2","first-page":"97","article-title":"Effect of recombinant interferon alpha 2 on clinical course of first episode genital herpes infection and subsequent recurrences","volume":"62","author":"Mendelson J","year":"1986","journal-title":"Genitourin Med"},{"key":"e_1_2_8_196_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/161.4.692"},{"key":"e_1_2_8_197_2","doi-asserted-by":"publisher","DOI":"10.1159\/000246483"},{"key":"e_1_2_8_198_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.1997.tb02293.x"},{"key":"e_1_2_8_199_2","first-page":"100","article-title":"The effectiveness of tromantadine in herpes simplex: double\u2010blind study","volume":"116","author":"Ahumada M","year":"1977","journal-title":"Ther Ggw"},{"key":"e_1_2_8_200_2","first-page":"XLI","article-title":"Tromantadine hydrochloride in the treatment of herpes genitalis. A double\u2010blind controlled study","volume":"120","author":"Altomare GF","year":"1985","journal-title":"G Ital Dermatol Venereol"},{"key":"e_1_2_8_201_2","first-page":"506","article-title":"Topical tromantadine in the treatment of genital herpes. A double\u2010blind placebo controlled study","volume":"40","author":"Petersen CS","year":"1993","journal-title":"Dan Med Bull"},{"key":"e_1_2_8_202_2","doi-asserted-by":"publisher","DOI":"10.1086\/516542"},{"key":"e_1_2_8_203_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.11.2996"},{"key":"e_1_2_8_204_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/3.suppl_A.131"},{"key":"e_1_2_8_205_2","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jama.1982.03330080035025","article-title":"Ineffectiveness of topical idoxuridine in dimethyl sulfoxide for therapy for genital herpes","volume":"248","author":"Silvestri DL","year":"1982","journal-title":"JAMA"},{"key":"e_1_2_8_206_2","first-page":"88","article-title":"Beta\u2010interferon for labial and genital herpes virus infection","volume":"116","author":"Glezerman M","year":"1989","journal-title":"Harefuah"},{"key":"e_1_2_8_207_2","doi-asserted-by":"publisher","DOI":"10.1258\/0956462001916533"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-4632.2009.04375.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-4632.2009.04375.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T23:15:10Z","timestamp":1697325310000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-4632.2009.04375.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,21]]},"references-count":206,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["10.1111\/j.1365-4632.2009.04375.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-4632.2009.04375.x","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,21]]},"assertion":[{"value":"2010-06-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}